NSCLC metastatic/molecular target

 
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 10/10/2019)

EGFR
Currently no trials

ALK
Currently no trials

KRAS
CLXH (Novartis) -> for 3th line and higher
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer. 
(currently on hold)

AMG510 (Amgen) -> for 2nd and 3rd line
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C.

RET
Currently no trials

BRAF
CLXH (Novartis) -> for 3th line and higher
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer. 
 (currently on hold)

C-MET
CINC280 (Novartis) -> for 1st and 2nd line
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer.
(only cohort 6 and 7 open)

ROS1
BFAST (Roche)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial).
(only cohort D open)